Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina /non–ST-elevation myocardial infarction ), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke.
From the U.S. FDA-approved label for Clopidogrel. Full label: DailyMed.
Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina /non–ST-elevation myocardial infarction ), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. Clopidogrel tablets should be administered in conjunction with aspirin.
From the U.S. FDA-approved label for Clopidogrel. Full label: DailyMed.
Acute coronary syndrome – Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. – Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days. Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose.
Directions from the U.S. FDA-approved label for Clopidogrel — your doctor or pharmacist may advise differently.
Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage Hypersensitivity to clopidogrel or any component of the product 4.1 Active Bleeding Clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. 4.2 Hypersensitivity Clopidogrel tablets are contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product.
Excerpt from the U.S. FDA-approved label for Clopidogrel. Talk to a pharmacist or doctor before use.
CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. Bleeding: Clopidogrel increases risk of bleeding. Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. Thrombotic thrombocytopenic purpura (TTP) has been reported. Cross-reactivity among thienopyridines has been reported. 5.1 Diminished Antiplatelet Activity in Patients with Impaired CYP2C19 Function Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite.
Warnings and precautions excerpt from the U.S. FDA-approved label for Clopidogrel — not a complete list. Talk to a pharmacist or doctor before use.
The following serious adverse reactions are discussed below and elsewhere in the labeling: Bleeding Thrombotic thrombocytopenic purpura Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Excerpt from the U.S. FDA-approved label for Clopidogrel — not a complete list. Talk to a pharmacist or doctor about side effects.
20 brands · 17 makers in the NepalDoc catalog — see the full Clopidogrel guide →
Store at 20° to 25°C (68° to 77°F); Protect from moisture.
Storage information from the U.S. FDA-approved label for Clopidogrel.
What is Cloflow?
Cloflow 75mg Tablet is a Clopidogrel medicine made by Aristo Pharmaceuticals Ltd. It comes as 75mg Tablet.
What is the generic name of Cloflow?
The generic name of Cloflow is Clopidogrel.
Which brands of Clopidogrel are available in Nepal?
20 brands of Clopidogrel are listed in the NepalDoc catalog, from 17 makers — including ANTICLOT 75MG Tablet, Antiplar 75mg Tablet, Articlean 75mg Tablet, Cidogril 75 MG Tablet, Clavix 75mg Tablet, Clavix 150 mg Tablet.
What are the side effects of Clopidogrel?
The following serious adverse reactions are discussed below and elsewhere in the labeling: Bleeding Thrombotic thrombocytopenic purpura Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.